The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
Eileen Mary O'Reilly
Research Funding - OncoMed
Lon S. Smith
No relevant relationships to disclose
Johanna C. Bendell
No relevant relationships to disclose
Fatima A. Rangwala
No relevant relationships to disclose
William Schmidt
No relevant relationships to disclose
Joe Stephenson
Research Funding - OncoMed
Ann Kapoun
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Lu Xu
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Dawn Hill
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Lei Zhou
Consultant or Advisory Role - OncoMed
Jakob Dupont
Employment or Leadership Position - OncoMed
Stock Ownership - OncoMed
Allen Lee Cohn
Research Funding - OncoMed